21 May 2009
Microvescicular liver graft steatosis as a risk factor of ipf (initial poor function) in relation to suboptimal donor parameters
B Cieślak, Z Lewandowski, M Urban, B Ziarkiewicz-Wróblewska, M KrawczykAnn Transplant 2009; 14(1): 43-44 :: ID: 880357
Abstract
Aim: To find out the role of microvesicular graft steatosis in relation to donor's parameters.
Material/Methods: 269 consecutive orthotopic liver transplantations were
performed in the Department between 2004 and 2006. Donor parameters
(age, BMI, ICU stay, hypotension, cardiac arrest, vasoactive agents, sodium concentration, AST, ALT, GGT, bilirubin and APTT) and percentage of microvesicular graft steatosis data were collected into the study. Endpoint of the study was dysfunction of the liver graft (AST or ALT >2500 IU/L or prothrombin index < 50% during first 7 days after OLTx - orthotopic liver transplantation).
Results: The increase of microvesicular steatosis by 12% results in significant aggravation of the risk of IPF by 50%.
Conclusions: The microvesicular steatosis is a risk factor of hepatic early dysfunction after liver transplantation. Moreover, it seems that recipients are more exposed to IPF, if the microsteatosis occurs with other suboptimal donor's parameters. The results are shown as an odds ratio for IPF in the group of optimal and suboptimal donors.
Keywords: Liver Transplantation
In Press
Original article
Urinary Chemokines CXCL9 and CXCL10 Are Non-Invasive Biomarkers of Kidney Transplant RejectionAnn Transplant In Press; DOI: 10.12659/AOT.944762
Original article
Risk Factors for Graft Failure After Penetrating Keratoplasty in Eastern China from 2018 to 2021Ann Transplant In Press; DOI: 10.12659/AOT.945388
Original article
Predictive Model for Post-Transplant Renal Fibrosis Using Ultrasound Shear Wave ElastographyAnn Transplant In Press; DOI: 10.12659/AOT.945699
Original article
The Long-Acting Glucagon-Like Peptide-2 Analog Apraglutide Enhances Intestinal Protection and Survival Afte...Ann Transplant In Press; DOI: 10.12659/AOT.945249
Most Viewed Current Articles
05 Apr 2022 : Original article 12,974
Impact of Statins on Hepatocellular Carcinoma Recurrence After Living-Donor Liver TransplantationDOI :10.12659/AOT.935604
Ann Transplant 2022; 27:e935604
22 Nov 2022 : Original article 10,077
Long-Term Effects of Everolimus-Facilitated Tacrolimus Reduction in Living-Donor Liver Transplant Recipient...DOI :10.12659/AOT.937988
Ann Transplant 2022; 27:e937988
12 Jan 2022 : Original article 9,421
Risk Factors for Developing BK Virus-Associated Nephropathy: A Single-Center Retrospective Cohort Study of ...DOI :10.12659/AOT.934738
Ann Transplant 2022; 27:e934738
15 Mar 2022 : Case report 7,180
Combined Liver, Pancreas-Duodenum, and Kidney Transplantation for Patients with Hepatitis B Cirrhosis, Urem...DOI :10.12659/AOT.935860
Ann Transplant 2022; 27:e935860